Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiation OncologyBCBS North Dakota IMRT Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - North DakotaPolicy 167

    Intensity Modulated Radiotherapy (IMRT) for Tumors in Close Proximity to Organs at Risk

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - North Dakota Policy 167 alerts

    Get alerted when Policy 167 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and preauthorization review for IMRT used for primary or metastatic tumors located close to organs at risk. Coverage depends on comparative 3D-CRT versus IMRT dose/volume analysis demonstrating that published organ dose constraints can be met only with IMRT.

    Policy Summary
    PayerBlue Cross Blue Shield - North Dakota
    PolicyIntensity Modulated Radiotherapy (IMRT) for Tumors in Close Proximity to Organs at Risk
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJanuary 1, 2026
    Next Review DateSeptember 2026
    Key ActionSubmit comparative 3D versus IMRT dose/volume histograms in color and a completed summary analysis with the preauthorization request.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Comparative treatment plans required
    6Dose/volume analysis components required
    3Published dose-constraint sources cited
    Met

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage stance
    Not metNoncovered scenario
    3 CPT / 2 HCPCSTreatment planning and delivery codes listed

    Medical Necessity Criteria

    Tumors in close proximity to organs at risk

    IMRT may be considered medically necessary when ALL of the following are met:

    Eligible tumor: The treatment is for a primary or metastatic tumor in close proximity to organs at risk.
    Comparative dosimetry submitted: Comparative 3D versus IMRT dose/volume histograms are submitted in color.

    The summary analysis, preferably in table format, is completed and submitted with the preauthorization request.

    Published constraints require IMRT: The completed summary analysis demonstrates that published dose/volume constraints for the organs at risk can be met only through IMRT.

    Quality-assurance procedures are not required for preauthorization.

    Not medically necessary

    IMRT is considered not medically necessary when the policy criteria are not met.

    Criteria not met: The tumor or submitted comparative planning analysis does not satisfy the policy requirements for medically necessary IMRT.

    Specific indications addressed by Policies 164, 165, or 166 should be reviewed under those policies.

    Medical necessity for tumors near organs at risk

    IMRT may be medically necessary when the policy criteria are met.

    IMRT medically necessary: IMRT reduces radiation to vital structures below recommended thresholds compared with alternative radiation therapy techniques.Below recommended dose thresholds for relevant vital structures

    Examples of organs at risk include the heart, spinal cord, and esophagus.

    IMRT is considered not medically necessary for treatment of tumors that do not meet the policy criteria.

    IMRT is considered not medically necessary when the tumor does not meet the policy criteria, including when comparative planning does not demonstrate that IMRT is necessary to reduce radiation to vital structures below the recommended dose thresholds compared with alternative radiation therapy techniques.

    Treatment Planning and Delivery Codes

    CPTCPT
    77301Intensity modulated radiotherapy plan, including dose volume histograms for target and critical structure partial tolerance specification.
    77338Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan.
    77385(IMRT), design and construction per IMRT plan Intensity modulated radiation treatment deliver (IMRT), includes guidance and tracking, when performed; simple (Deleted 01/01/2026).
    77386Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex (Deleted 01/01/2026).
    HCPCSHCPCS
    G6015Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session (Deleted 01/01/2026).
    G6016Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session (Deleted 01/01/2026).
    Image fusion and treatment planningCPT
    77399Unlisted procedure, medical radiation physics, dosimetry and treatment devices, and special services; correct code for image fusion performed to provide enhanced delineation of target and normal critical structures, considered part of treatment planning.

    Authorization and Documentation Requirements

    Prior Authorization

    Preauthorization With Comparative Dose Analysis

    Preauthorization is required for IMRT requests under this policy. Submit comparative 3D-versus-IMRT dose/volume histograms in color and a completed summary analysis, preferably using the policy template, with the preauthorization request. The analysis must demonstrate that only IMRT can meet published organ-at-risk dose/volume constraints; quality-assurance procedures for the 3D and IMRT plans are not required with preauthorization.

    Documentation Required

    Clinical Documentation Required

    Submit the clinical information needed to establish that the policy criteria are met, including the patient’s clinical history, physical examination or chart notes, and relevant imaging reports.

    • Clinical history
    • Physical or chart notes
    • Relevant imaging reports documenting that the policy criteria are met for medical necessity

    Clinical and Technical Background

    Intensity-modulated radiotherapy (IMRT) uses computer-optimized, intensity-modulated radiation beams to improve conformality around the tumor and reduce radiation exposure to surrounding normal tissues. This approach is intended to limit radiation to organs at risk, such as the heart, spinal cord, and esophagus, compared with alternative radiation therapy techniques.

    Key Terms

    Organs at risk
    DefinitionNormal tissues whose radiation sensitivity may significantly influence treatment planning and/or the prescribed radiation dose.
    Clinical concernThese tissues may be particularly vulnerable to clinically important complications from radiation toxicity.
    Intensity-modulated radiotherapy (IMRT)
    DefinitionA radiation-therapy technique that conforms closely to the tumor, modulates the intensity of overlapping radiation beams, and uses computer-based inverse treatment planning.
    Beam and planning featuresIMRT uses multiple-shaped treatment fields and a multileaf collimator coupled to a computer algorithm to optimize beam location, shape, and intensity.
    Treatment objectivesThe plan specifies the target dose, acceptable dose heterogeneity, adjacent normal tissues to avoid, and acceptable dose limits for adjoining organs at risk.
    Policy Summary
    PayerBlue Cross Blue Shield - North Dakota
    PolicyIntensity Modulated Radiotherapy (IMRT) for Tumors in Close Proximity to Organs at Risk
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJanuary 1, 2026
    Next Review DateSeptember 2026
    Key ActionSubmit comparative 3D versus IMRT dose/volume histograms in color and a completed summary analysis with the preauthorization request.
    SourceLink
    On This Page
    Medical Necessity CriteriaTreatment Planning and Delivery CodesAuthorization and Documentation RequirementsClinical and Technical BackgroundKey Terms
    Documentation Required

    Comparative Dosimetry Analysis

    Provide color comparative 3D-versus-IMRT dose/volume histograms and a completed analysis identifying the organ at risk, dose constraint, source of the constraint, dose achieved through 3D planning, dose achieved through IMRT, and whether the dose constraint can be met only with IMRT. The documentation must show that IMRT is needed to meet constraints not achievable through 3D planning.

    • Organ at risk
    • Dose constraint employed
    • Source of the constraint
    • Dose achieved via 3D planning
    • Dose achieved via IMRT
    • Yes/no answer to: “Can the dose constraint only be met with IMRT?”
    Denial Risk

    Criteria Not Met

    IMRT is considered not medically necessary for tumors that do not meet the policy criteria. Refer to Medicine policies 164, 165, or 166 for specific indications addressed in those policies.

    Denial Risk

    Incomplete Review Documentation Risks Denial

    Missing clinical, imaging, comparative dosimetry, or summary-analysis documentation may affect the review and decision outcome. Ensure all required materials are complete before submission, including the supporting analysis table and every required comparative-dosimetry element.

    • Clinical history and physical/chart notes
    • Relevant imaging reports
    • Color 3D-versus-IMRT dose/volume histograms
    • Completed summary analysis documenting all required fields
    Denial Risk

    Organ-at-Risk Dose Criteria Must Be Met

    IMRT is not medically necessary when it does not reduce radiation to vital structures below recommended thresholds compared with alternative radiation techniques such as 3D planning. Coverage requires documentation that only IMRT can meet the applicable published organ-at-risk dose constraints.

    • Policy examples of organs at risk include the heart, spinal cord, esophagus, brainstem, brachial plexus, and cauda equina.
    • The comparative analysis must demonstrate the organ-at-risk dose benefit required by the policy.
    Three-dimensional conformal radiation therapy (3D-CRT)
    DefinitionRadiation therapy planned with three-dimensional imaging, usually from computed tomography scans, to delineate the tumor, adjacent normal tissues, and nearby organs at risk for radiation damage.
    Dose-planning methodComputer algorithms estimate the cumulative radiation dose delivered to each volume of interest by summing the contribution from each shaped beam.
    Treatment deliveryPatient positioning, radiation-portal reproducibility, and immobilization methods maintain consistent beam axes across treatment sessions.